GSK3B and tauopathy: After we defined by AAV-Tau injection in the ERC that protein Tau made use of both the TA and PP pathways to reach the hippocampal formation (Fig. S1), we went on to assess the effects of protein Tau alone and in combination with GSK3β on the white-matter tracts within the CA1 SLM in both pre-clinical tauopathy models.